PEPGNasdaq

PepGen Inc.

Healthcare·Rare Disease·Phase 2·Boston, MA, United States
Rare Disease

PepGen Inc. (PEPG): 4 pipeline candidates · ~21 mo cash runway · 5 clinical trials. Updated within the last hour.

5.7/10

BioSniper Score

5-factor signal · derived from public data

Cash Runway5.8

20.9 months

Financial Health9.5

D/E 0.17

Pipeline Maturity6.0

Lead: Phase 2

Pipeline Breadth7.2

4 candidates

Catalyst MomentumN/A

N/A

Insider Signal0.1

0 buys · 7 sells (180d)

A transparent, data-derived signal for PepGen Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$105.8M

Cash

$42.1M

Quarterly Burn

$18.4M

Runway

20.9 mo

Revenue

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Mar 2028
Today~23 mo out
Catalyst within runway

Pipeline (4 candidates)

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

92

Total value held

$95.9M

HolderSharesValue
ra capital management, l.p.20,064,545$35.5M
commodore capital lp4,475,000$7.9M
vanguard capital management llc3,875,398$6.9M
viking global investors lp3,482,434$6.2M
laurion capital management lp2,750,855$4.9M
millennium management llc2,079,143$3.7M
kalehua capital management llc1,729,961$3.1M
adar1 capital management, llc1,607,638$2.8M
pictet asset management holding sa1,306,783$2.3M
blackrock, inc.1,277,784$2.3M

Showing top 10 of 92 institutional holders of PepGen Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.

5 clinical trials·CEO: Dr. James G. McArthur Ph.D.

Frequently asked questions

How many drug candidates are in PepGen Inc.'s pipeline?

PepGen Inc. (PEPG) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is PepGen Inc.'s lead drug candidate?

PepGen Inc.'s most advanced tracked candidate is iv infusion (Phase 2) for Duchenne Muscular Dystrophy (DMD).

What is PepGen Inc.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, PepGen Inc. has approximately 20.9 months of cash runway.

What is PepGen Inc.'s market capitalization?

PepGen Inc.'s market capitalization is approximately $105.8M.

Who is the CEO of PepGen Inc.?

Dr. James G. McArthur Ph.D. is the chief executive officer of PepGen Inc. (PEPG).

Get the full picture on PepGen Inc.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.